Alongside Enhertu, Daiichi and AstraZeneca's Datroway also showed a 43% reduction in risk of progression or death, marking continued progress in breast cancer treatment. The survival benefit was seen ...
The event in Washington, DC saw Bailey highlight a decline in the UK's potential growth rate from 2.5% to 1.5% over the past 15 years. He linked this to lower productivity growth, an ageing population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback